Rinri Therapeutics

Executive Summary

Rinri Therapeutics is a UK-based clinical-stage biotechnology company pioneering regenerative cell therapies for sensorineural hearing loss (SNHL), a condition affecting millions worldwide with no approved disease-modifying treatments. Founded on groundbreaking research from the University of Sheffield, the company is developing first-in-class approaches to restore hearing by rekindling lost neural connections in the inner ear. Rinri's lead candidate, Rincell-1, is an autologous cell therapy designed to regenerate spiral ganglion neurons, aiming to improve hearing function in patients with severe SNHL. The company has advanced Rincell-1 into Phase 1 clinical trials, with initial safety and efficacy data expected in the coming months. Rinri's platform technology has the potential to address a large unmet medical need, offering a transformative alternative to hearing aids and cochlear implants. The company's strong scientific foundation and early clinical progress position it as a leader in the emerging field of regenerative otology.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 safety and efficacy data readout for Rincell-150% success
• Q4 2026FDA or MHRA IND/CTA clearance for second indication or next-generation candidate40% success
• TBDStrategic partnership or licensing deal for Rincell-1 in major markets30% success